Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTZ1XV)

Drug Name
NBBCC Drug Info
Synonyms
N-Butyl-beta-carboline-3-carboxylate; beta-Ccb; 84454-35-3; N-Butyl beta-carboline-3-carboxylate; butyl; butyl 9H-pyrido[3,4-b]indole-3-carboxylate; beta-CARBOLINE-3-CARBOXYLIC ACID BUTYL ESTER; WGNGIELOOKACSB-UHFFFAOYSA-N; Tocris-0405; Biomol-NT_000274; AC1Q66WT; I(2)-CCB; GTPL2374; SCHEMBL2214572; CHEMBL148296; BPBio1_001057; AC1L2U46; CHEBI:34867; Butyl -carboline-3-carboxylate; DTXSID90233426; MolPort-023-275-884; HMS3266M05; Butyl beta-carboline-3-carboxylate; ZINC2555360; Butyl; n-butyl-beta-carboline-3-carboxylate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
128618
ChEBI ID
CHEBI:34867
CAS Number
CAS 84454-35-3
TTD Drug ID
DMTZ1XV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glycine receptor (GlyR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [3]
ZD-9379 DM3KYO4 Cerebrovascular ischaemia 8B1Z Phase 1 [4]
UK-240455 DMSCXB7 Nerve injury ND56.4 Phase 1 [5]
MDL-27531 DMC60S8 Epilepsy 8A60-8A68 Phase 1 [6]
Gavestinel DM8IL1U Nerve injury ND56.4 Discontinued in Phase 2 [7]
GV-196771 DMFN21T Migraine 8A80 Discontinued in Phase 2 [8]
GW 468816 DMQ92WF Tobacco dependence 6C4A.2 Discontinued in Phase 2 [9]
M-241247 DMIY51U Cerebrovascular ischaemia 8B1Z Terminated [10]
GINKOLIDE B DMLIM7B Sepsis 1G40-1G41 Terminated [11]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycine receptor (GlyR) TTZ8EM9 GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN Not Available [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2374).
2 Developmental regulation of beta-carboline-induced inhibition of glycine-evoked responses depends on glycine receptor beta subunit expression. Mol Pharmacol. 2005 May;67(5):1783-96.
3 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
4 Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
5 UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
6 MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
7 Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54.
8 First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6.
9 A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
11 Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.